MedTrace Logo

Carnitine Supplementation and Skeletal Muscle Function

NCT02692235 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2019-05-23

Study results available
· View outcomes & findings →

Summary

Research project objectives The primary aim of the current research project is to use carnitine supplementation as the anti-inflammatory intervention for exploring the relationship between inflammation and associated with aging reduction of skeletal muscle mass.

Hypothesis The carnitine supplementation modulates the blood cytokines concentration. Anti-inflammatory intervention delay the reduction of skeletal muscle mass associated with aging

Conditions

Interventions

DIETARY_SUPPLEMENT

carnitine

1500 mg/d l-carnitine-l-tartrate

DIETARY_SUPPLEMENT

placebo

isonitrogenous

Sponsors & Collaborators

  • National Science Centre, Poland

    collaborator OTHER_GOV

  • Gdansk University of Physical Education and Sport

    lead OTHER

Principal Investigators

  • Robert A Olek, PhD · Gdansk University of Physical Education and Sport

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-03-31
Completion
2017-07-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02692235 on ClinicalTrials.gov